RT Journal Article
SR Electronic
T1 The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.16.21263684
DO 10.1101/2021.09.16.21263684
A1 Conway-Morris, Andrew
A1 Sharrocks, Katherine
A1 Bousfield, Rachel
A1 Kermack, Leanne
A1 Maes, Mailis
A1 Higginson, Ellen
A1 Forrest, Sally
A1 Pereira-Dias, Joana
A1 Cormie, Claire
A1 Old, Tim
A1 Brooks, Sophie
A1 Hamed, Islam
A1 Koenig, Alicia
A1 Turner, Andrew
A1 White, Paul
A1 Floto, R. Andres
A1 Dougan, Gordon
A1 Gkrania-Klotsas, Effrossyni
A1 Gouliouris, Theodore
A1 Baker, Stephen
A1 Navapurkar, Vilas
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.16.21263684.abstract
AB Background The COVID-19 pandemic has overwhelmed the respiratory isolation capacity in hospitals; many wards lacking high-frequency air changes have been repurposed for managing patients infected with SARS-CoV-2 requiring either standard or intensive care. Hospital-acquired COVID-19 is a recognised problem amongst both patients and staff, with growing evidence for the relevance of airborne transmission. This study examined the effect of air filtration and ultra-violet (UV) light sterilisation on detectable airborne SARS-CoV-2 and other microbial bioaerosols.Methods We conducted a crossover study of portable air filtration and sterilisation devices in a repurposed ‘surge’ COVID ward and ‘surge’ ICU. National Institute for Occupational Safety and Health (NIOSH) cyclonic aerosol samplers and PCR assays were used to detect the presence of airborne SARS-CoV-2 and other microbial bioaerosol with and without air/UV filtration.Results Airborne SARS-CoV-2 was detected in the ward on all five days before activation of air/UV filtration, but on none of the five days when the air/UV filter was operational; SARS-CoV-2 was again detected on four out of five days when the filter was off. Airborne SARS-CoV-2 was infrequently detected in the ICU. Filtration significantly reduced the burden of other microbial bioaerosols in both the ward (48 pathogens detected before filtration, two after, p=0.05) and the ICU (45 pathogens detected before filtration, five after p=0.05).Conclusions These data demonstrate the feasibility of removing SARS-CoV-2 from the air of repurposed ‘surge’ wards and suggest that air filtration devices may help reduce the risk of hospital-acquired SARS-CoV-2.Funding Wellcome Trust, MRC, NIHRCompeting Interest StatementVilas Navapurkar is the founder, Director, and shareholder of Cambridge Infection Diagnostics Ltd. Andrew Conway-Morris, Paul White, Gordon Dougan and Stephen Baker are members of the Scientific Advisory Board of Cambridge Infection Diagnostics Ltd. Theodore Gouliouris has received a research grant from Shionogi. R Andres Floto has received research grants and/or consultancy payments from GSK, AZ, Chiesi, Shionogi, Insmed, Thirty Technology. Effrossyni Gkrania-Klotsas has received a National Institute of Health Research Greenshoots AwardClinical TrialService evaluation of ability of a device to remove bioaerosol not involving patient dataFunding StatementThis work was supported by a Wellcome senior research fellowship to Stephen Baker (215515/Z/19/Z). Andrew Conway Morris is supported by a Clinician Scientist Fellowship from the Medical Research Council (MR/V006118/1). Mailis Maes and Sally Forrest are funded by the National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK National Institute for Health Research confirmed that ethical approval was not required for this work.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request to the corresponding author.